TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21701167
Drug: Omacor™ 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor™ 2 g/day
Study: 10702452
Drug: ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.2% wt/vol + sufentanil 0.75 microg/mL
Study: 10702452
Drug: ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.2% wt/vol + sufentanil 1.0 microg/mL
Study: 10702452
Drug: ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.2% wt/vol + sufentanil 0.5 microg/mL
Study: 7645792
Drug: Behavioral Therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Therapy (BT, n = 12)
Study: 7645792
Drug: Total group
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total group (all treatments)
Study: 23253298
Drug: Collagen sealant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen sealant patch (CSP) plus standard treatment
Study: 20458443
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy (cisplatin or carboplatin)
Study: 25327732
Drug: YAZ (drospirenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: YAZ (drospirenone 3 mg and ethinylestradiol 20 microg)
Study: 10362048
Drug: N-isobutyrylcysteine (NIC)
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-isobutyrylcysteine (NIC) 300 mg b.i.d. for 24 weeks
Study: 7595717
Drug: lenograstim 5
Normalized name: LENOGRASTIM
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenograstim 5 micrograms/kg/d by once‐daily injection from day 4 to day 13
Study: 2406695
Drug: Infant stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant stimulation followed by physical therapy
Study: 2406695
Drug: Neurodevelopmental physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental physical therapy
Study: 7425833
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of phenytoin orally the evening before and on the morning of the operation
Study: 7425833
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of phenytoin orally the evening before and on the morning of the operation
Study: 31383723
Drug: Combination norms
Normalized name: K Norm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination norms letter (both social norms)
Study: 25262617
Drug: Advocate(®) (2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advocate(®) (2.5% moxidectin+10% imidacloprid) applied monthly, biweekly, or weekly
Study: 25262617
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin (IVR) at 500 μg/kg daily
Study: 22709744
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (150 mg to 300 mg twice a day, adjusted based on creatinine clearance and plasma levels)
Study: 22709744
Drug: Warfarin (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (dosing according to current practice guidelines)
Study: 7994785
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Adriamycin (group A)
Study: 7994785
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg epirubicin (group B)
Study: 7994785
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg pirarubicin (group C)
Study: 26940547
Drug: Community-wide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide treatment
Study: 26940547
Drug: School-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based treatment
Study: 22839442
Drug: Paricalcitol (2‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (2‐4 g/day)
Study: 22839442
Drug: Calcitriol (1‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (1‐6 g/day orally)
Study: 20421406
Drug: lopinavir-ritonavir with
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir-ritonavir with efavirenz (3 tablets [600/150 mg], 4 capsules [533/133 mg], 2 tablets [400/100 mg] twice a day)
Study: 20421406
Drug: lopinavir-ritonavir with
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir-ritonavir with nevirapine (3 tablets [600/150 mg], 4 capsules [533/133 mg], 2 tablets [400/100 mg] twice a day)
Study: 20421406
Drug: lopinavir-ritonavir without
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir-ritonavir without NNRTIs (2 tablets [400/100 mg] twice a day)
Study: 16086616
Drug: Topiramate 300
Normalized name: topiramate 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 300 mg/day
Study: 12643293
Drug: Interferon-alpha2b plus
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2b plus ribavirin (1,000 to 1,200 mg per day)
Study: 9350362
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine + 100 micrograms fentanyl
Study: 9350362
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg morphine + 100 micrograms fentanyl
Study: 9350362
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine alone
Study: 9350362
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg morphine alone
Study: 6939318
Drug: Antidepressants (isocarboxazide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (isocarboxazide, lithium citrate)
Study: 6939318
Drug: Antidepressants (zimelidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (zimelidine, nomifensine)
Study: 6939318
Drug: Antidepressants (imipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (imipramine oxide, mianserin)
Study: 6939318
Drug: Antidepressants (maprotiline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (maprotiline, nortriptyline, clomipramine, imipramine, amitriptyline)
Study: 29024881
Drug: Antenatal reflexology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal reflexology (six weekly 30-minute treatments)
Study: 29024881
Drug: Sham (footbath)
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham (footbath) treatments
Study: 24431385
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% (160 mg)
Study: 17608775
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment with a proton pump inhibitor (PPI), clarithromycin, and amoxicillin
Study: 17608775
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy for 10 days
Study: 17608775
Drug: PPI, levofloxacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI, levofloxacin, and amoxicillin for 10 days
Study: 11596588
Drug: Fluorouracil-based adjuvant
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil-based adjuvant therapy
Study: 2139916
Drug: Ketoconazole (KTZ)
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole (KTZ) 400 mg/d
Study: 2139916
Drug: Ketoconazole (KTZ)
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole (KTZ) 800 mg/d
Study: 631536
Drug: Heparin-Dihydergot (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-Dihydergot (2 x 0.5 mg DHE or 2 x 5000 IU of heparin)
Study: 631536
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DHE and heparin
Study: 631536
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (3 x 0.5 g)
Study: 27939124
Drug: Low thiamin
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low thiamin concentration fish sauce (2 g/L)
Study: 27939124
Drug: High thiamin
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High thiamin concentration fish sauce (8 g/L)
Study: 25923435
Drug: Sugammadex 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 3.0 mg/kg
Study: 2699571
Drug: Toothpaste A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste A (specific formulation not mentioned)
Study: 2699571
Drug: Toothpaste B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste B (specific formulation not mentioned)
Study: 28405611
Drug: AAV2-GAD gene
Normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV2-GAD gene therapy
Study: 16698237
Drug: Ceftazidime dosage
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime dosage administered by continuous infusion, individualized using a proposed formula based on creatinine clearance and target concentration at steady state.
Study: 16698237
Drug: Ceftazidime dosage
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime dosage administered by continuous infusion using the proposed formula.
Study: 11320105
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (two 2.5-mg patches per day)
Study: 7970646
Drug: Multivitamin supplement
Normalized name: Vi-Daily Multivitamin Supplement Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplement (containing 0.8 mg of folic acid)
Study: 2835892
Drug: 6.5 g
Normalized name: ALCOHOL 196.5 g in 503 mL TOPICAL SPRAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 g dietary fibre supplement
Study: 27875501
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training with ibuprofen (400 mg)
Study: 23279217
Drug: TZP-102 10
Normalized name: TZP-102
DrugBank: TZP-102 (DB16129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TZP-102 10 mg, 20 mg, 40 mg
Study: 23279217
Drug: TZP-102 (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: TZP-102 (any dose)
Study: 21639938
Drug: Educational interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational interventions consisting of a standardized teaching course aimed at doctors and nurses, lasting 6 hours split into three 2-hour blocks with subsequent monthly refresher courses.
Study: 16856219
Drug: Flunitrazepam (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (1.0 mg; 1.3 mg)
Study: 9377171
Drug: Recombinant interleukin‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interleukin‐1 receptor antagonist (placebo-controlled)
Study: 8383943
Drug: WIN 54954
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WIN 54954 (600 mg per dose, two doses on the first day followed by three doses on each of the subsequent 5 days)
Study: 3978010
Drug: Bupivacaine-fentanyl mixtures
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-fentanyl mixtures (all doses)
Study: 28990633
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training focused on ankle strengthening and mobility, twice per week for 10 weeks.
Study: 22801062
Drug: Albumin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin (single intravenous dose at the time of LVP)
Study: 22801062
Drug: Vasoconstrictor combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoconstrictor combination of octreotide (20 mg intramuscular injection monthly) and midodrine (10 mg oral, 3 times/day)
Study: 18761243
Drug: Remifentanil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.5 microg/kg followed by 1 mg/kg of propofol
Study: 18761243
Drug: Fentanyl 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.5 microg/kg followed by 1 mg/kg of propofol
Study: 12063371
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin (among S. aureus carriers)
Study: 10589634
Drug: Clonidine-morphine group
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine-morphine group (oral clonidine 5 microg/kg + epidural morphine 2 mg)
Study: 10589634
Drug: Clonidine-morphine group
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine-morphine group
Study: 10589634
Drug: Placebo-morphine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-morphine group
Study: 8609105
Drug: Acute repair
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute repair with a synthetic ligament-augmentation device (Group 2)
Study: 6870163
Drug: Clonixin 300
Normalized name: clonixin
DrugBank: Clonixin (DB09218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonixin 300 mg three times daily
Study: 6870163
Drug: Oxyphenbutazone 100
Normalized name: oxyphenbutazone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxyphenbutazone 100 mg three times daily
Study: 27354118
Drug: QAW039 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAW039 (500 mg once daily)
Study: 21779093
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume (LV) alginate preload (9.9 g alginate in 330 ml)
Study: 21779093
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume (HV) alginate preload (15.0 g alginate in 500 ml)
Study: 12211496
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose aspirin (325 mg)
Study: 8949670
Drug: Iodixanol 320
Normalized name: IODIXANOL 320mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol 320 mgI ml‐1 (Visipaque)
Study: 8949670
Drug: Iohexol 350
Normalized name: iohexol 350 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol 350 mgI ml‐1 (Omnipaque)
Study: 8949670
Drug: Iodixanol (60-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol (60-100 ml)
Study: 8949670
Drug: Iohexol (60-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol (60-100 ml)
Study: 26009712
Drug: Acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 400 mg tablets thrice daily for 7 days
Study: 26009712
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (cetirizine 10 mg OD and calamine)
Study: 21999640
Drug: Technosphere inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere inhaled insulin + insulin glargine (TI+G)
Study: 21999640
Drug: Premixed aspart
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premixed aspart insulin 70/30
Study: 19735497
Drug: NIDCAP (treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIDCAP (treatment, E)
Study: 12606844
Drug: Flupenthixol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol (mean daily dose 6.6 mg/day)
Study: 12606844
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean daily dose 3.6 mg/day)
Study: 10173126
Drug: Micronised fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fenofibrate 200 mg
Study: 10173126
Drug: Micronised fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fenofibrate 200 mg (type IIa)
Study: 10173126
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg (type IIa)
Study: 10173126
Drug: Micronised fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fenofibrate 200 mg (type IIb)
Study: 10173126
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg (type IIb)
Study: 8453546
Drug: Phosphorus-32 as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphorus-32 as primary adjuvant treatment
Study: 8453546
Drug: Phosphorus-32 as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphorus-32 as consolidating therapy after second-look surgery
Study: 8453546
Drug: Phosphorus-32 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphorus-32 treatment
Study: 2937598
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 to 160 mg twice a day)
Study: 2937598
Drug: Nitrendipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (5 to 20 mg twice a day)
Study: 24516038
Drug: octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: octreotide LAR 30 mg intramuscularly every 4 weeks
Study: 24516038
Drug: Physician's treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's treatment of choice in case of diarrhea
Study: 18827176
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/day (titrated to 10 mg if BP goal not achieved)
Study: 11392163
Drug: OAT-omeprazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAT-omeprazole (2 x 20 mg), amoxycillin (2 x 1000 mg), tinidazole (2 x 500 mg)
Study: 11392163
Drug: OAC-omeprazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC-omeprazole (2 x 20 mg), amoxycillin (2 x 1000 mg), clarithromycin (2 x 250 mg)
Study: 8842111
Drug: Arteflene (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arteflene (25 mg/kg)
Study: 1503438
Drug: S-1108 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1108 (200 mg TID for 8 days)
Study: 26884585
Drug: Apatinib 850
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 850 mg once daily
Study: 15989829
Drug: Relaxation techniques
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation techniques (RT) combined with conventional treatment
Study: 12466335
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg androstenedione
Study: 12466335
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg androstenedione)
Study: 10466913
Drug: Rhesus‐human reassortant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus‐human reassortant rotavirus tetravalent vaccine (RRV‐TV)
Study: 8554942
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 g kg‐1)
Study: 8554942
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 g kg‐1) + Caffeine (400 mg)
Study: 1939687
Drug: Trimeprazine tartrate
Normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimeprazine tartrate (sedative medication) prescribed in a reducing dose over the first 10 days of extinction
Study: 1939687
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered double-blind
Study: 28648803
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg twice-daily)
Study: 11460023
Drug: Nonoxynol-9 gel
Normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoxynol-9 gel (52.5 mg)
Study: 10423625
Drug: edrophonium (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: edrophonium (1 mg/kg) and atropine (0.01 mg/kg) reversal (E/A)
Study: 3860788
Drug: Prostaglandin F2
Normalized name: Prostaglandin F2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin F2 alpha (16 mg diluted in 40 mL of saline)
Study: 29469430
Drug: Conventional nursing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional nursing plus solution focused approach
Study: 18514729
Drug: Prednisolone (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (35 mg once a day)
Study: 10417579
Drug: Topical onion
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical onion gel extract
Study: 10417579
Drug: Topical emollient
Normalized name: HPR Topical Emollient Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical emollient ointment (petrolatum based)
Study: 1904681
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (2 months before hysterectomy)
Study: 1904681
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no agonist)
Study: 31455700
Drug: Proactive case
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive case detection by CHWs with daily home visits and doorstep services
Study: 15019156
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg/day for one year)
Study: 9669136
Drug: 2% Minoxidil
Normalized name: MINOXIDIL 2 g in 100 mL TOPICAL LIQUID [2% Minoxidil hair growth serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Minoxidil therapy
Study: 7520956
Drug: Intraperitoneal 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal 5-fluorouracil and intravenous folinic acid Days 1-6 after operation
Study: 4212040
Drug: Gentamicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin plus daily granulocyte transfusion
Study: 28001306
Drug: Doxapram (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram (plasma concentration 1,000‐3,500 ng/mL)
Study: 28001306
Drug: Alfentanil (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (plasma concentration 100‐200 ng/mL)
Study: 24253812
Drug: Low SMUG1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low SMUG1 protein expression in ER+ cohort receiving adjuvant endocrine therapy
Study: 24253812
Drug: Low SMUG1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low SMUG1 protein expression in ER- cohort receiving adjuvant chemotherapy